<![CDATA[BiolineRX News]]> http://biolinerx.com/RSS.asp he 07/01/2013 720 <![CDATA[BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & Company ]]> http://biolinerx.com/default.asp?PageID=16&ItemID=195 17/05/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=195 <![CDATA[BioLineRx to Present at the Oppenheimer 14th Annual Israeli Conference on May 12th ]]> http://biolinerx.com/default.asp?PageID=16&ItemID=193 09/05/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=193 <![CDATA[BioLineRx Reports First Quarter 2013 Results]]> http://biolinerx.com/default.asp?PageID=16&ItemID=192 07/05/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=192 <![CDATA[BioLineRx's BL-7010, for the Treatment of Celiac, to be Presented at Two Leading Conferences]]> http://biolinerx.com/default.asp?PageID=16&ItemID=191 02/05/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=191 <![CDATA[BioLineRx pipeline returns to the winner's circle]]> http://biolinerx.com/default.asp?PageID=17&ItemID=189 30/04/2013 http://biolinerx.com/default.asp?PageID=17&ItemID=189 <![CDATA[BioLineRx to Report First Quarter 2013 Results on May 7, 2013]]> http://biolinerx.com/default.asp?PageID=16&ItemID=187 30/04/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=187 <![CDATA[BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C]]> http://biolinerx.com/default.asp?PageID=16&ItemID=186 29/04/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=186 <![CDATA[BioLineRx to Present at the 12th Annual Needham Healthcare Conference in New York on April 30, 2013]]> http://biolinerx.com/default.asp?PageID=16&ItemID=184 18/04/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=184 <![CDATA[BioLineRx Announces Positive Phase II Results for BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease ]]> http://biolinerx.com/default.asp?PageID=16&ItemID=183 BL-7040 met the primary efficacy endpoint of the study
BL-7040 was also shown to be safe and well tolerated 
]]> 17/04/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=183 <![CDATA[BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040, for Treatment of Leukemia]]> http://biolinerx.com/default.asp?PageID=16&ItemID=182 Partial results expected in Q4 2013
Final results expected in H2 2014
]]> 10/04/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=182 <![CDATA[BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia ]]> http://biolinerx.com/default.asp?PageID=16&ItemID=180 20/03/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=180 <![CDATA[BioLineRx Receives Approval from French Regulatory Authorities to Commence a Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C ]]> http://biolinerx.com/default.asp?PageID=16&ItemID=173 13/03/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=173 <![CDATA[BioLineRx Reports Year End 2012 Financial Results]]> http://biolinerx.com/default.asp?PageID=16&ItemID=172 12/03/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=172 <![CDATA[BioLineRx's EDP-14, for Treatment of Severe and Persistent Asthma, to Enter the Company's Main Therapeutic Pipeline as BL-9010 ]]> http://biolinerx.com/default.asp?PageID=16&ItemID=170 28/02/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=170 <![CDATA[BioLineRx to Report Fourth Quarter and Year End 2012 Results on March 12, 2013 ]]> http://biolinerx.com/default.asp?PageID=16&ItemID=178 26/02/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=178 <![CDATA[BioLineRx Announces Closing of $8 Million Offering of American Depositary Shares]]> http://biolinerx.com/default.asp?PageID=16&ItemID=176 13/02/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=176 <![CDATA[BioLineRx Announces Offering of American Depositary Shares]]> http://biolinerx.com/default.asp?PageID=16&ItemID=169 06/02/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=169 <![CDATA[BioLineRx Provides Clarification Regarding Interim Analysis of CLARITY Trial for BL-1020]]> http://biolinerx.com/default.asp?PageID=16&ItemID=175 04/02/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=175 <![CDATA[BioLineRx to Present at the 2013 BIO CEO & Investor Conference in New York on February 12th]]> http://biolinerx.com/default.asp?PageID=16&ItemID=174 31/01/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=174 <![CDATA[BioLineRx to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug during week of March 18, 2013]]> http://biolinerx.com/default.asp?PageID=16&ItemID=166 07/01/2013 http://biolinerx.com/default.asp?PageID=16&ItemID=166